Analysis for LLY

📈 Growth & Financial Trajectory

Revenues rose from roughly $8.77B in Q1 2024 to $19.29B in Q4 2025, roughly doubling across the 8-quarter window. Net income also advanced from about $2.24B to $6.64B, despite quarterly fluctuations that reflect mix shifts and investment activity. The eight quarters show an uptrend with stronger cadence from mid-2024 onward.

💰 Margins & Cash Flow

Gross margins hovered around the high 70s to low 80s percent, stabilizing around ~82% across most quarters, with a brief expansion in late 2024. Operating cash flow generally positive, while investing activities produced meaningful outflows in several quarters; total cash flow remained reasonably cash-positive in many periods, with occasional net cash outflows depending on capex and acquisitions.

🛡️ Balance Sheet & Liquidity

Assets ($112B) exceed liabilities ($85B), yielding a solid equity base around $26B by Q4 2025. Current assets vs current liabilities remained healthy (current ratio roughly 1.2–1.6 across quarters), supporting liquidity despite ongoing investments.

⚠️ Key Drivers & Risks

• Drivers: Strong margin discipline and a growing product portfolio support earnings power; favorable operating leverage as volume rises.
• Risks: Regulatory and pricing pressures, potential patent/product cycle risks, and high sensitivity to macro factors in pharma reimbursement.